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Intraplaque hemorrhage causes adaptive remodelling of macrophages towards a protective phenotype specialized towards handling
iron and lipid overload, denoted Mhem. The Mhem phenotype expresses elevated levels of hemoglobin (Hb) scavenger receptor,
CD163, capable of endocytosing pro-oxidant free Hb complexed to acute phase protein haptoglobin (Hp). It is notable that
individuals homozygous for the Hp 2 allele (a poorer antioxidant) are at increased risk of cardiovascular disease compared
to the Hp 1 allele. In this study, we examined whether scavenging of polymorphic Hp:Hb complexes differentially generated
downstream anti-inflammatory signals in cultured human macrophages culminating in interleukin (IL)-10 secretion. We describe
an anti-inflammatory signalling pathway involving phosphatidylinositol-3-kinase activation upstream of Akt phosphorylation
(pSer473Akt) and IL-10 secretion. The pathway is mediated specifically through CD163 and is blocked by anti-CD163 antibody
or phagocytosis inhibitor. However, levels of pSer473Akt and IL-10 were significantly diminished when scavenging polymorphic
Hp2-2:Hb complexes compared to Hp1-1:Hb complexes (𝑃 < 0.05). Impaired anti-inflammatory macrophage signaling through a
CD163/pAkt/IL-10 axis may thus represent a possible Hp2-2 disease mechanism in atherosclerosis.
1. Introduction
Intraplaque hemorrhage is a common complication of
atherosclerosis and is linked to plaque progression, especially
in diabetes [1–4]. However, work from independent groups
has demonstrated that macrophages at zones of hemor-
rhage may exert some level of homeostatic control through
adaptive remodelling towards an Mhem phenotype capable
of handling iron and lipid overload [5–7]. Scavenging of
haptoglobin:hemoglobin (Hp:Hb) complexes via CD163 is
part of this adaptive process, linked to secretion of anti-
inflammatory cytokine interleukin (IL)-10 and elevation
of heme oxygenase (HO)-1 [8–10]. Analogous protective
pathways are evoked by free diffusion of purified heme
or by phagocytosis of damaged erythrocytes via CD204,
leading to the proposal that a final common pathway is
instigated by accumulation of intracellular heme capable of
transcriptionally activating genes involved in iron handling
and cholesterol efflux (e.g., HO-1 and liver X receptor) via
transcription factors Nrf2 and activating transcription factor
(ATF)-1 [11, 12]. Although the atheroprotective properties of
the Mhem macrophage phenotype is therefore well estab-
lished, the role of proximal signalling pathways linked to anti-
inflammatory IL-10 secretion via CD163-dependent uptake of
Hb:Hp remains to be fully understood.
In addition to IL-10, immunoregulatory IL-6 cytokine has
been consistently reported downstream of CD163 [8, 13, 14].
However, the earliest IL-6 studies using cross-linking anti-
CD163 antibodies may not have adequately discriminated
between surface versus endocytosis-dependent effector path-
ways [13, 14]. Whether downstream signals require simple
cross-linking of CD163 at the cell surface or phagocytosis
2 International Journal of Inflammation
of the entire Hp:Hb complex is an important distinction,
since Hp2-2:Hb binds more avidly than Hp1-1:Hb to CD163
at the surface but, conversely, is more poorly internalised
into the cell [15, 16]. More recent investigations employing
native Hp:Hb ligand appeared to suggest poor or even lack of
dependence on CD163 for IL-6 or IL-10 signalling pathways,
depending on the type of polymorphic haptoglobin variant
employed [17, 18]. Since the haptoglobin 2 allele is linked
to a host of adverse clinical cardiovascular events, [19–23] it
is important to understand Hp genotype-dependent disease
mechanisms in CD163+ macrophages in greater detail, to
guide informed interdictions in vulnerable individuals.
Here we have examined IL-10 signalling pathways during
scavenging of polymorphic Hp2-2:Hb versus Hp1-1:Hb com-
plexes in CD163+ human monocyte-derived macrophages.
We identify a specificAkt/IL-10 pathway that is comparatively
underinduced during the scavenging of Hp2 complexes.
2. Materials and Methods
2.1. Reagents and Antibodies. Human Hb (Ao), human Hp
(phenotypes 1-1 and 2-2), and colchicinewere purchased from
Sigma-Aldrich (Poole, UK). Anti-human CD163 monoclonal
antibody clones RM3/1, Ki-m8, and 5C6-FATwere purchased
from Bachem (Merseyside, UK), clone GHI/61 from BD
Pharmingen (Oxford, UK), and clone Ber-MAC3 from Dako
(Cambridge, UK). Polyclonal anti-Akt and anti-phosphoAkt
(Ser473) antibodies were purchased from Cell Signalling
Technology, Inc. (Beverley, MA). The phosphoinositide-3-
kinase (PI-3K) inhibitor, Ly294002, was purchased from
Alexis Corporation (Bingham, UK). Endotoxin determina-
tions were made using the GCL-1000 LAL chromogenic
endpoint assay (Cambrex Bio Science, Wokingham, UK).
2.2. Hb:Hp Treatment of Macrophage Cultures. Humanmon-
ocytes were isolated from venous blood and differentiated
into CD163+ macrophages in vitro as described [8]. Hb:Hp
complexes were generated by dissolving equimolar amounts
of Hb and Hp in growth medium. Hb, Hp, or Hb:Hp were
added at final concentrations of 1mg/mL unless otherwise
stated to monocyte/macrophage cultures prior to incubation
for 24 hours and collection of supernatants and/or cell lysates
for IL-10 and Akt analysis, respectively. Hb or Hp batches
containing detectable endotoxin (>5 pg/mL) were discarded.
Supernatants and cell lysates were stored in aliquots at −70∘C
prior to analysis. In some experiments, the PI-3K inhibitor
Ly294002was added at 50, 25, 12.6, and 6.25 𝜇mol/L final con-
centrations. ActinomycinD and cycloheximidewere added at
a concentration of 1𝜇g/mL and colchicine at a concentration
range between 10 and 1.25 𝜇mol/L. None of the inhibitors
at the concentrations used exhibited significant macrophage
cellular cytotoxicity [24]. Anti-CD163monoclonal antibodies
were added at a final concentration of 20𝜇g/mL, previously
shown to be neutralizing [8].
2.3. Enzyme Linked Immunosorbent Assays. IL-10 concen-
trations in culture supernatants were determined by ELISA
technique (Quantikine; R&D Systems, Abingdon, UK)
according to themanufacturer’s recommendations. Phospho-
Akt levels in cell lysates, collected in buffer consisting of 1%
Triton X-100, 25mmol/L sodium deoxycholate, 150mmol/L
NaCl, 50mmol/L Tris pH 7.4, 4mmol/L EDTA, 200𝜇mol/L
sodium orthovanadate, 10mmol/L sodium pyrophosphate,
100mmol/L sodium fluoride, 1mmol/L phenylmethylsul-
fonyl fluoride, and 5% protease inhibitor cocktail (Sigma
Aldrich), were measured by pSer473 Akt kit (Biosource,
Camarillo, CA) according to manufacturer’s instructions. All
samples were measured in duplicate and results expressed
as mean cytokine concentration (pg/mL) or pAkt activity
(U/mg) ± SEM from 𝑛 = 3 experiments.
2.4. Western Blot Analysis. Monocytes/macrophages were
lysed in buffer, as described for the phospho-Akt ELISA,
and proteins were separated by SDS-PAGE on a 12.5% gel
prior to transfer to Immobilon-P membranes (Millipore
Corporation, Bedford, MA). Equal loading of lanes was
confirmed by estimation of lysate protein content using the
Bio-Rad Dc protein assay (Bio-Rad, Hercules, CA). Induc-
tion of pSer473Akt was established relative to total Akt by
probing blots with polyclonal antibody against pSer473Akt,
followed by stripping and reprobingwith total Akt. Blots were
developed with an enhanced chemiluminescence substrate
(AmershamPharmacia BiotechUKLtd, Little Chalfont, UK).
2.5. Statistical Analysis. Statistical comparisons between
Hp1-1:Hb and Hp2-2:Hb groups were performed using an
unpaired Student’s t-test. Multiple group comparisons of
pSer473Akt activitywere performedusing a onewayANOVA
with a Student-Newman-Keuls posttest. Statistical analysis
was performed using GraphPad Prism (GraphPad Prism
Software, Inc., San Diego, CA), and significance was assumed
at 𝑃 < 0.05.
3. Results
3.1. Impaired IL-10 Secretion following CD163-Dependent
Scavenging of Hp2-2:Hb. IL-10 induction has been linked to
CD163 receptor engagement [8, 13, 14, 17, 18]. Differential IL-
10 responses by CD163+ macrophages were therefore exam-
ined in the presence of polymorphic Hp:Hb complexes. The
addition of Hp:Hb complexes across a range of concentra-
tions to in vitro differentiated CD163+ macrophages revealed
significantly impaired IL-10 induction in the case of Hp2-2.
At concentrations within the range of plasma haptoglobin
(0.1–2 g/L) [18, 25], the IL-10 response to Hp2-2:Hb was
significantly diminished compared to Hp1-1:Hb (e.g., at 1 g/L:
3509 ± 169 pg/mL versus 6739 ± 678, 𝑃 < 0.01; Figure 1(a)).
The timecourse of IL-10 induction to either type of Hp:Hb
complex was relatively slow, with a peak at 48 h (Figure 1(b)).
Consistent with the slow kinetic, IL-10 secretion required
prior transcription and protein synthesis, as it was abrogated
in the presence of actinomycin D or cycloheximide (data not
shown). In agreement with previous observations [8, 15, 17]
and again repeated here, IL-10 induction required formation
of a Hp:Hb protein complex, since neither Hb alone, nor Hp
alone yielded significant IL-10 secretion (Figure 1(c)). A panel
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Figure 1: CD163-dependent IL-10 secretion following scavenging of polymorphic Hp:Hb complexes. (a) Effect of increasing concentrations
of polymorphic Hp:Hb complexes on IL-10 secretion by CD163+ human monocyte-derived macrophages at 24 h. (b) Timecourse of IL-10
secretion following addition of polymorphic Hp:Hb complexes at 1mg/mL. (c) IL-10 secretion by CD163+ macrophages stimulated with Hb
alone, Hp1-1, Hp2-2, or polymorphic Hp:Hb complexes (1mg/mL) at 24 h. (d) Effect of a panel of anti-CD163 antibodies (20 𝜇g/mL) on IL-10
secretion induced by polymorphicHb:Hp complexes (1mg/mL) at 24 h. All IL-10 assays were carried out in duplicate, and results are expressed
as mean IL-10 (pg/mL) ± SEM from 𝑛 = 3–9 experiments. ∗𝑃 < 0.01.
of five anti-CD163 antibodies showed a similar inhibitory
profile to either type of complex with the notable exception of
the function blocking anti-CD163 antibody RM3/1 [8]. RM3/1
abolished IL-10 secretion in response to Hp1-1:Hb but only
weakly inhibited the response to Hp2-2:Hb (Figure 1(d)).
3.2. Signaling Pathways Linked to CD163-Dependent Hp:Hb
Scavenging. The IL-10 response to either type of Hp required
phagocytosis of complexes, since it was blocked in the pres-
ence of the phagocytosis inhibitor colchicine (Figure 2(a)).
A screen of PI-3K, PKC, p42/44 MAP kinase, and p38
MAP kinase signaling pathway inhibitors revealed that the
IL-10 response to Hp:Hb complex scavenging was dose
dependently inhibited by the PI-3K inhibitor LY294002
(Figure 2(b)).This was true for Hp2-2:Hb as well as Hp1-1:Hb
complexes. The pan-PKC inhibitor bisindolylmaleimide, the
p42/44 MAP kinase inhibitor U0126, and p38 MAP kinase
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Figure 2: Effect of pharmacological inhibitors on Hp dependent IL-10 secretion. Effect of (a) colchicine (1.25–10𝜇mol/L) and (b) Ly294002
(6.25–50 𝜇mol/L) on IL-10 release by CD163+ human monocyte-derived macrophages stimulated with polymorphic Hp:Hb complexes
(1mg/mL) for 24 h. Results are expressed as mean IL-10 (pg/mL) ± SEM from 𝑛 = 3–4 experiments.
inhibitor SB203580, used at a concentration range known to
inhibit cytokine secretion in the same cell preparation against
calcific microcrystals [24], had no effect on IL-10 secretion
(data not shown).
To further explore signaling pathways linked to CD163
downstream of PI-3 kinase, phosphorylation of Akt
was investigated. Phosphorylation of Akt at serine 473
(pSer473Akt) was examined by Western blot as well as
phosphoSer473Akt-specific ELISA: both assays showed
phosphorylation of Ser473Akt and this was inhibited
significantly by anti-CD163 antibody RM3/1 or colchicine
(Figures 3(a) and 3(b)). Akt phosphorylation required
upstream PI-3Kinase activation, as it was abrogated in the
presence of PI-3Kinase inhibitor Ly294002 (Figures 3(a) and
3(b)). Akt phosphorylation was markedly impaired following
scavenging of Hp2-2:Hb complexes compared to Hp1-1:Hb,
across a broad concentration range (e.g., at 1 g/L: 0.20 ±
0.02U/mg versus 0.50 ± 0.10, 𝑃 < 0.05; Figure 3(c)).
4. Discussion
The central role of Hp in complexing free Hb and mediating
its clearance through CD163 led us to consider whether
the Hp2-2 genotype, clinically associated with cardiovas-
cular complications, may show impaired anti-inflammatory
signaling engagement downstream of CD163. The model
chosen for this work (human monocytes differentiated for
7 days in culture) benefits from the absence of exogenously
added differentiating agents (e.g., steroids) and has been
validated against human macrophages differentiated in vivo:
equivalent functional responses to Hp:Hb scavenging were
noted in CD163+ macrophages recovered from human skin
blisters during the cutaneous inflammatory response to
cantharidin [8]. The CD163/Akt/IL-10 axis identified here
adds to a growing understanding that homeostatic signalling
pathways may be triggered in CD163+ macrophages during
hemoglobin scavenging and that these are impaired in the
case of polymorphic Hp2-2 protein. Our data add a cellular
dimension to the innate antioxidant properties recognised
for Hp variants (Hp1-1 superior to Hp2-1 superior to Hp2-2)
[4, 26, 27] and suggest a plausible new disease mechanism
linking Hp2-2 with atherothrombosis.
Our findings are consistent with previous reports on
the relative inability of Hp2-2:Hb complexes to trigger IL-
10 responses [17, 18] and may explain why previous reports
noted an apparent lack of CD163 receptor usage by polymor-
phic Hp2-2:Hb variants [17, 18]. In those studies, RM3/1 was
employed as the blocking antibody. Here we confirm that
RM3/1 is the most potent blocking antibody against Hp1-
1:Hb induced IL-10 secretion, out of a screen of five anti-
CD163 antibodies (RM3/1, Ki-M8, 5C6-FAT, GHI/61, and
Bermac-3). However, RM3/1 exhibited only weak blocking
against Hp2-2:Hb complexes. Hence, it is not likely that
Hp2-2:Hb signals through a different (unknown) receptor
pathway. The evidence presented here with other blocking
antibodies (Bermac3 and GHI/61) as well as the phagocytosis
inhibitor colchicine strongly suggests that both types of
Hp:Hb complexes are endocytosed via CD163.
Results from the panel of blocking antibodies also have
implications for the way in which signals are generated
through CD163. The elegant structure-function analysis of
CD163 protein [28], which combined ligand binding studies
in solution with a comprehensive epitope map of ten anti-
CD163 antibodies, failed to detect any direct ligand-blocking
property for RM3/1. Only Ki-m8 and Edhu-1, mapping to
the ligand binding scavenger receptor cysteine-rich (SRCR)
domain 3, directly inhibitedHp:Hb binding to CD163 in solu-
tion. Since these same two antibodies behaved as agonistic
antibodies when added to cells [8, 13, 14], this supports the
concept that cross-linking of two or more ligand-binding
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Figure 3: Hp:Hb scavenging-dependent Akt phosphorylation. (a) Representative Western blot showing phosphorylated Akt (pSer473) and
total Akt in lysates from macrophages stimulated with Hp1-1:Hb (1mg/mL; HH in legend) for 20 minutes in the presence and absence of
blocking anti-CD163 antibody clone RM3/1 (20 𝜇g/mL; RM3/1 in legend), colchicine (2.5𝜇mol/L; colch in legend), or phosphoinositol 3-
kinase inhibitor Ly294002 (12.5𝜇mol/L; Ly in legend). (b) Quantitative ELISA determination of Akt (pSer473) phosphorylation in cell lysates
from macrophages treated as in (a) above. (c) Comparison of Hp2-2:Hb versus Hp1-1:Hb scavenging on Akt phosphorylation in cell lysates,
as measured by pSer473Akt-specific ELISA. Results in (b) and (c) are expressed as pSer473Akt (U/mg) ± SEM from three experiments.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01.
domains on CD163 must be required for signal generation, as
originally proposed [15]. Out of the panel of ten anti-CD163
antibodies previously mapped, RM3/1 uniquely mapped to
the last SRCR domain (domain 9, immediately proximal to
the plasma membrane) [28]. This suggests that its function
blocking property relates to an ability to block dimerization of
CD163 at the membrane following cross-linking with native
Hp1-1:Hb holo-dimer. SinceHp2-2 exists as a largermultimer,
consisting of 3–8 subunits, thismight explainwhyRM3/1 only
partially blocks IL-10 signal production in response to the
multimeric complex.
We describe a hitherto unappreciated signalling pathway
following Hp:Hb complex endocytosis, requiring Ser473Akt
phosphorylation and culminating in IL-10 secretion. We
recognise the limitations posed through the use of a phar-
macologic inhibitor of PI-3 kinase, but phosphorylation of
Ser473Akt was verified both at Western blot and quantitative
intracellular ELLISA levels. Adenoviral infection approaches
to further dissect the signalling pathway were not successful,
since infection even with empty vectors triggered phospho-
rylation of Akt, therefore ruling out this approach (data not
shown). Past studies that used adenovirus to investigate sig-
nalling pathways in macrophages used differentiating agents
not compatible with the CD163+ endpoint and our cells may
therefore have behaved differently [29].
Studies carried out prior to the identification of Hp:Hb
as ligand for CD163 employed a cross-linking anti-CD163
antibody, EDhu-1, and reported IL-6 secretion that was
casein kinase II and PKC dependent [13, 14]. Secretion of
IL-6 in our hands, in response to Hp:Hb, was not specific
to CD163, since it did not require Hp complex formation
with Hb, did not require an intact microtubular assembly
for phagocytosis, and was not blocked by function-blocking
antibodies or a PI-3K inhibitor (data not shown). Our own
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results do not therefore support IL-6 as an effector molecule
downstream of CD163, whereas IL-10 was confirmed and was
Hp genotype dependent. Alternative receptor mechanisms
and endotoxin contamination were excluded as confounding
sources of intracellular signals. Mac-1 was eliminated as a
possible alternative candidate receptor for haptoglobin [30].
Endotoxin levels in all cell cultures were below 5 pg/mL and
inhibition of IL-10 secretion by phagocytic inhibitors also
ruled out endotoxin as a possible trigger. Our previous work
has shown that above a threshold concentration of>10 ng/mL
of Hp:Hb complexes, all or none commitment to the CD163+
phenotype occurs via an IL-10/CD163 feedback loop [31].
This scenario is consistent with observations that CD163+
macrophages closely associate with areas of hemorrhage [10,
31].
In summary, the present study has identified an PI-
3/Akt signaling pathway contributing to IL-10 secretion via
CD163+-dependent hemoglobin scavenging, a pathway that
is impaired during the scavenging of polymorphic Hp2-
2 complexes. This adds not only to our understanding
of cardiovascular disease susceptibility for Hp2-2 but may
also be relevant to the protection of the vasculature and
kidneys from heme-mediated oxidative injury secondary
to hemolysis [32–35], especially in predisposing conditions
like diabetes, sickle cell anemia, or leukaemia treatment
[16, 36, 37]. In conjunction with previous observations in
atherosclerotic plaques [5, 12, 31], we propose that CD163+
macrophages may act as a homeostatic brake on plaque
inflammation secondary to hemorrhage, in an Hp genotype
dependent manner.
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